USPTO Examiner AL AWADI DANAH J - Art Unit 1615

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18630105PHARMACEUTICAL FORMULATIONS CONTAINING GABOXADOL FOR THERAPEUTIC TREATMENTApril 2024September 2025Abandon1801NoNo
18627508Implantable Device for Sustained Release of a Macromolecular Drug CompoundApril 2024September 2025Allow1720NoNo
18586970SUCKABLE AND/OR MELT-IN-MOUTH TABLET BASED ON HYALURONIC ACID AND CHONDROITIN SULPHATE AND SALTS THEREOFFebruary 2024October 2025Allow2030NoNo
18437420EXTENDED RELEASE COMPOSITIONS COMPRISING PYRIDOSTIGMINEFebruary 2024September 2024Allow800NoNo
18402862Methods And Kits For Reducing Microplastics Levels And/Or Reducing Or Minimizing Microplastics Accumulation Rates In SubjectsJanuary 2024December 2025Allow2300NoNo
18386399ETHYL 2-[9-(2-HYDROXYQUINOLIN-3-YL)-1,8-DIOXO-3,4,9,10-TETRAHYDROACRIDINE-10-YL]-ACETATE AS AN ANTIMICROBIAL COMPOUNDNovember 2023March 2024Allow410NoNo
184968214,5-BIS(4-METHOXYPHENYL)-1-HEXYL-2-(4-NITROPHENYL)-1H-IMIDAZOLE AS AN ANTIMICROBIAL COMPOUNDOctober 2023February 2024Allow410NoNo
18493075LIPSTICKOctober 2023February 2026Allow2800NoNo
184930722-(BENZO[D]OXAZOL-2-YL)-N'-(PICOLINOYLOXY)ACETIMIDAMIDE AS AN ANTIMICROBIAL COMPOUNDOctober 2023January 2024Allow300NoNo
183814549-(2-HYDROXYPHENYL)-10-[3-(DIMETHYLAMINO)PROPYL]-3,4,6,7,9,10- HEXAHYDROACRIDINE-1,8(2H,5H)-DIONE AS AN ANTIMICROBIAL COMPOUNDOctober 2023January 2024Allow300NoNo
18373611METHODS OF INCREASING MAGNESIUM BIOAVAILABILITY AND ABSORPTIONSeptember 2023September 2025Allow2320NoNo
18466404COSMETIC PRODUCTS INCLUDING BIS-CARBOXY SILICONE POLYMER COMPONENTSeptember 2023April 2025Abandon1920NoNo
18460941Ready-To-Use Potassium Phosphates In Sodium Chloride SolutionsSeptember 2023December 2023Allow300NoNo
18360514DRY POWDER COMPOSITIONS OF TREPROSTINIL PRODRUGS AND METHODS OF USE THEREOFJuly 2023September 2024Allow1410NoNo
18262131DRUG DELIVERY COMPOSITION, METHOD FOR PRODUCING SAME AND USE THEREOFJuly 2023October 2025Allow2700NoNo
18345919COMPOSITIONS AND METHODS COMPRISING ENERGY ABSORBING MATERIALS FOR FOLLICULAR DELIVERYJune 2023June 2025Allow2421YesNo
18329268DRUG DELIVERY SYSTEM COMPRISING A NON-STEROIDAL ANTI-INFLAMMATORY (NSAID) AND A PROGESTOGENIC COMPOUND AND METHODS FOR MANUFACTURINGJune 2023November 2024Abandon1810NoNo
18322065DERMAL SKIN PROTECTANT AND CARRIERMay 2023May 2025Allow2420YesNo
18315605Implantable Device for Sustained Release of a Macromolecular Drug CompoundMay 2023January 2024Allow800NoNo
18312624WAX OF NATURAL ORIGIN FOR COSMETIC PRODUCTSMay 2023December 2025Allow3101NoNo
18033144OIL-BASED COSMETICApril 2023February 2026Abandon3410NoNo
18136916EXTENDED RELEASE COMPOSITIONS COMPRISING PYRIDOSTIGMINEApril 2023October 2023Allow510NoNo
18303138Process for Transfer Resistance Polymers in Pigmented ProductsApril 2023December 2025Abandon3210NoNo
18191874AQUEOUS COSMETICMarch 2023April 2024Allow1311NoNo
18121679NUTRACEUTICAL COMPOSITIONS AND METHODS FOR DIETARY ALLEVIATION OF POLYCYSTIC OVARY SYNDROMEMarch 2023October 2023Allow721YesNo
18245039SOLID FORMS OF A CDK4 INHIBITORMarch 2023November 2025Allow3210NoNo
18179777COMPOSITIONS COMPRISING SILK FIBROIN PARTICLES AND USES THEREOFMarch 2023August 2024Allow1720NoNo
18168958PHARMACEUTICAL COMPOSITION COMPRISING EICOSAPENTAENOIC ACID AND NICOTINIC ACID AND METHODS OF USING SAMEFebruary 2023October 2024Abandon2011NoNo
18104950ANTIMICROBIAL COMPOSITION INCLUDING AN ACYL LACTYLATE AND A GLYCOL AND METHODS OF INHIBITING MICROBIAL GROWTH UTILIZING THE SAMEFebruary 2023September 2025Allow3240NoNo
18097097METHOD FOR PRODUCING POWDER LEADS AND PRODUCTS PRODUCED THEREWITHJanuary 2023May 2024Allow1611NoNo
18005095FILM COATED TABLETJanuary 2023March 2026Allow3820NoNo
18148860INJECTABLE PREPARATIONDecember 2022February 2024Allow1410NoNo
18013764Use of Self-Assembled NanocrystalsDecember 2022December 2025Abandon3501NoNo
18012975Method for Treating MelanomaDecember 2022January 2026Abandon3610NoNo
18011215DRUG COMPRISING PLGA NANOPARTICLES LOADED WITH CAPE TARGETED WITH ANGIOPEP-2 PEPTIDEDecember 2022December 2025Abandon3610NoNo
18059008COMPOSITION FOR COATING TABLETNovember 2022November 2025Abandon3541NoNo
18070186ANTIMICROBIAL COMPLEXESNovember 2022January 2024Abandon1401NoNo
17999193PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING PANCREATIC CANCER ASSOCIATED WITH RON MUTATION AND METHOD USING SAMENovember 2022December 2025Abandon3710NoNo
17981080SENSITIZING COMPOSITION USING ELECTROMAGNETIC WAVES FOR THERMAL THERAPY OF CANCERS, AND CANCER THERAPY USING SAMENovember 2022May 2023Allow700NoNo
17915865PHYTOECDYSONES AND DERIVATIVES THEREOF FOR USE IN TREATING DISORDERED RESPIRATORY FUNCTION ON VIRAL INFECTIONSeptember 2022October 2025Allow3710NoNo
17950638NOVEL CERIUM OXIDE NANOCOMPLEX AND A COMPOSITION FOR PREVENTING OR TREATING CEREBRAL INFARCTION COMPRISING THE SAMESeptember 2022April 2024Abandon1910NoNo
17911781IDEBENONE FOR THE TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) IN PATIENTS DIAGNOSED WITH A CORONAVIRUS INFECTIONSeptember 2022September 2025Allow3610NoNo
17945054Vitamins and Alpha Keto Acid Compositions for Use in a Treatment Program for Chronic Kidney Disease PatientsSeptember 2022August 2024Allow2320YesNo
17945043Vitamins and Alpha Keto Acid Compositions for Use in a Treatment Program for Chronic Kidney Disease PatientsSeptember 2022May 2024Allow2010YesNo
17908132COSMETIC COMPOSITION WITH OPTIMIZED STARCH AND COSMETIC APPLICATIONS THEREOFAugust 2022October 2025Allow3810YesNo
17893991DRY POWDER COMPOSITIONS OF TREPROSTINIL PRODRUGS AND METHODS OF USE THEREOFAugust 2022May 2023Allow900NoNo
17798217OIL-IN-OIL EMULSIFIED COSMETICAugust 2022November 2025Abandon3920NoNo
17881991DOUBLE-STRUCTURED STICK COSMETIC AND MANUFACTURING METHOD THEREOFAugust 2022January 2024Allow1811NoNo
17797637PHARMACEUTICAL COMPOSITION CONTAINING REGORAFENIB AND A STABILIZING AGENTAugust 2022December 2025Abandon4001NoNo
17876348DOSAGE FORM COATING COMPOSITION AND METHOD OF MAKING AND USING THE SAMEJuly 2022May 2025Abandon3430NoYes
17790857SOLID LIP COSMETICJuly 2022July 2025Abandon3720NoNo
17787998COLONIC PURGATIVE COMPOSITIONJune 2022September 2025Abandon3920YesNo
17842691Implantable Pharmaceutical Composition Prepared From Components Consisting of Calcium Sulfate Alpha-Hemihydrate, Vancomycin and TobramycinJune 2022March 2024Abandon2101NoNo
17783678DISPERSION SOLUTION OF COMPLEX OF CERIUM OXIDE NANOPARTICLE WITH PROTEIN, METHOD OF SCAVENGING REACTIVE SPECIES, AND METHOD OF PRODUCING DISPERSION SOLUTION OF COMPLEX OF CERIUM OXIDE NANOPARTICLE WITH PROTEINJune 2022February 2026Allow4411NoNo
17783945CELLULOSE NANOCRYSTAL EFFECT PIGMENTS FOR COSMETIC APPLICATIONSJune 2022October 2025Allow4011NoNo
17757060DOSAGE FORM COMPRISING AN ALKALINE AGENT AND AN ENTERIC COATING LAYERJune 2022February 2026Allow4521YesNo
17831955USE OF HIGHER DOSES OF MODIFIED RELEASE HUPERZINE FORMULATIONSJune 2022August 2025Allow3950NoNo
17779566CO-AMORPHOUS FORMS OF BETA-LACTOGLOBULIN AND A DRUG SUBSTANCEMay 2022January 2026Allow4421NoNo
17777925AQUEOUS MIXTURES COMPRISING CELLULOSE NANOCRYSTALS AND SULFONATED POLYESTERMay 2022September 2025Allow4011YesNo
17772699DIETARY SUPPLEMENTApril 2022October 2025Allow4240YesNo
17726312Clear Nail Top Coat Compositions And Methods Of MakingApril 2022May 2025Abandon3610NoNo
17769678Clear Nail Top Coat Compositions And Methods Of MakingApril 2022June 2025Abandon3810NoNo
17716200CONTROLLED RELEASE SOLID DOSE FORMSApril 2022November 2025Abandon4311NoNo
17711122STORAGE STABLE SINCALIDE FORMULATIONSApril 2022January 2023Allow910NoNo
17765196PROTOPANAXATRIOL (PPT)-TYPE COMPOUNDS AS ACTIVE INGREDIENTS IN INSECTICIDE PRODUCTSMarch 2022March 2025Abandon3601NoNo
17701004PHARMACEUTICAL COMPOSITIONS COMPRISING AFATINIBMarch 2022September 2023Allow1810NoNo
17761725ANTIPERSPIRANT COMPOSITIONSMarch 2022December 2025Abandon4530NoNo
17642589PROCESS FOR PRODUCING A PHARMACEUTICAL FORMULATION COMPRISING CRYSTALLINE AND AMORPHOUS FRACTIONS OF AN ACTIVE SUBSTANCEMarch 2022December 2024Abandon3301NoNo
17683840METHOD FOR PRODUCING WEARABLE COATINGMarch 2022May 2023Allow1400NoNo
17652559SELF-THERAPEUTIC NANOPARTICLE FOR ENHANCED TOPICAL DELIVERY TO SKIN KERATINOCYTES AND TREATING SKIN INFLAMMATIONFebruary 2022May 2025Allow3841NoNo
17638538SOLID COMPOSITION CONTAINING AMORPHOUS, POORLY WATER-SOLUBLE MATERIAL, AND METHOD FOR PRODUCING SAMEFebruary 2022July 2025Allow4011NoNo
17637841SOLID COSMETICFebruary 2022June 2025Allow4020NoNo
17636661NO SCENT NO BITEFebruary 2022April 2025Abandon3801NoNo
17636732METHOD FOR PRODUCING A BIOACTIVE COMPONENT-CONTAINING NANO-COMPOSITE, AND A MONTMORILLONITE-BASED, BIOACTIVE COMPONENT-CONTAINING NANO-COMPOSITEFebruary 2022May 2025Allow3911NoNo
17633699DIETARY SUPPLEMENTS TO AMELIORATE DIETARY INADEQUACIES RELATED TO BRAIN HEALTH OR NEURODEGENERATIVE DISEASES, AND METHODS TO DESIGN DIETARY SUPPLEMENTSFebruary 2022January 2026Allow4721YesNo
17633226NOVEL COMPOUNDS FOR SKIN LIGHTENINGFebruary 2022March 2025Abandon3710NoNo
17629760MEDICATION COATED WITH HEMP OR OTHER CANNABINOIDJanuary 2022April 2025Abandon3811NoNo
17627493CHEWING GUM COMPOSITIONS FOR THE TREATMENT OF MENSTRUAL PAINJanuary 2022April 2025Abandon3910NoNo
17597526FOOD COMPOSITIONS FOR WEIGHT MANAGEMENTJanuary 2022February 2026Allow4921NoNo
17646794OIL-DISPERSED COMPOSITION AND COSMETICS FOR LIP CARE USING THE SAMEJanuary 2022November 2023Allow2321NoNo
17566015METHODS OF TREATMENT USING ULTRASMALL NANOPARTICLES TO INDUCE CELL DEATH OF NUTRIENT-DEPRIVED CANCER CELLS VIA FERROPTOSISDecember 2021November 2023Allow2210NoNo
17557105LONG WEAR LIQUID ANHYDROUS COMPOSITIONDecember 2021March 2024Allow2611NoNo
17553648DEODORANT COMPOSITIONSDecember 2021January 2025Abandon3710NoNo
17550117EXTENDED RELEASE COMPOSITIONS COMPRISING PYRIDOSTIGMINEDecember 2021January 2023Allow1321YesNo
17549495ANTICANCER COMPOSITIONSDecember 2021July 2024Abandon3120NoNo
17618256DEODORANT COMPOSITIONSDecember 2021January 2025Abandon3810NoNo
17526266SUGAR-FREE LIP SCRUB COMPOSITIONS AND USES THEREOFNovember 2021October 2023Abandon2320YesNo
17610727Powder CosmeticNovember 2021July 2025Allow4420NoNo
17513276METHODS OF INCREASING MAGNESIUM BIOAVAILABILITY AND ABSORPTIONOctober 2021September 2023Allow2211NoNo
17507369PHARMACEUTICAL FORMULATIONS CONTAINING GABOXADOL FOR THERAPEUTIC TREATMENTOctober 2021May 2024Abandon3111NoNo
17502181DRUG DELIVERY CARRIER INCLUDING PLGA AND BETA-CYCLODEXTRIN CONTAINING DRUGOctober 2021January 2024Abandon2711NoNo
17501237STABLE BENZIMIDAZOLE FORMULATIONOctober 2021March 2026Allow5350YesNo
17499001Ready-To-Use Potassium Phosphates In Sodium Chloride SolutionsOctober 2021September 2023Allow2300NoNo
17490797METHOD FOR TREATING MYOPIA AND APPLICATION IN PREPARATION OF MEDICAMENTSeptember 2021May 2024Abandon3121YesNo
17484725DRUG DELIVERY SYSTEM FOR TREATMENT OF CANCERSeptember 2021June 2025Allow4420NoNo
17480892HAIR CONDITIONING COMPOSITIONSeptember 2021April 2024Abandon3020NoNo
17439829COMPOSITIONS COMPRISING CURCUMIN AND COENZYME Q10September 2021August 2024Abandon3511NoNo
17476801TREATING MALE INFERTILITY SECONDARY TO SPERM OXIDATIVE STRESSSeptember 2021August 2025Abandon4740YesNo
17475741LAVAGE TECHNIQUES AND VIRUCIDAL COMPOSITIONS COMPRISING HYPOCHLOROUS SOLUTIONSSeptember 2021March 2025Abandon4230NoNo
17473826Dental Local Anesthetic SolutionSeptember 2021February 2023Abandon1721NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner AL-AWADI, DANAH J.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
22
Examiner Affirmed
15
(68.2%)
Examiner Reversed
7
(31.8%)
Reversal Percentile
48.3%
Lower than average

What This Means

With a 31.8% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
85
Allowed After Appeal Filing
18
(21.2%)
Not Allowed After Appeal Filing
67
(78.8%)
Filing Benefit Percentile
27.9%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 21.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner AL-AWADI, DANAH J - Prosecution Strategy Guide

Executive Summary

Examiner AL-AWADI, DANAH J works in Art Unit 1615 and has examined 802 patent applications in our dataset. With an allowance rate of 52.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 34 months.

Allowance Patterns

Examiner AL-AWADI, DANAH J's allowance rate of 52.6% places them in the 14% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by AL-AWADI, DANAH J receive 2.68 office actions before reaching final disposition. This places the examiner in the 78% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by AL-AWADI, DANAH J is 34 months. This places the examiner in the 42% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +15.2% benefit to allowance rate for applications examined by AL-AWADI, DANAH J. This interview benefit is in the 55% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 18.4% of applications are subsequently allowed. This success rate is in the 17% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 20.3% of cases where such amendments are filed. This entry rate is in the 25% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 84.2% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 65% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 62.1% of appeals filed. This is in the 40% percentile among all examiners. Of these withdrawals, 58.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 61.6% are granted (fully or in part). This grant rate is in the 66% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 3.0% of allowed cases (in the 79% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.5% of allowed cases (in the 55% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.